A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients

被引:207
作者
Dai, HY
van't Veer, L
Lamb, J
He, YD
Mao, M
Fine, BM
Bernards, R
de Vijver, MV
Deutsch, P
Sachs, A
Stoughton, R
Friend, S
机构
[1] Merck & Co Inc, Merck Res Labs, W Point, PA 19486 USA
[2] Rosetta Inpharmat LLC, Seattle, WA USA
[3] Netherlands Canc Inst, Div Diagnost Oncol Radiotherapy & Mol Carcinogene, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Ctr Biomed Genet, Amsterdam, Netherlands
[5] GHC Technol Inc, La Jolla, CA USA
关键词
D O I
10.1158/0008-5472.CAN-04-3953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer comprises a group of distinct subtypes that despite having similar histologic appearances, have very different metastatic potentials. Being able to identify the biological driving force, even for a subset of patients, is crucially important given the large population of women diagnosed with breast cancer. Here, we show that within a subset of patients characterized by relatively high estrogen receptor expression for their age, the occurrence of metastases is strongly predicted by a homogeneous gene expression pattern almost entirely consisting of cell cycle genes (5-year odds ratio of metastasis, 24.0; 95% confidence interval, 6.0-95.5). Overexpression of this set of genes is clearly associated with an extremely poor outcome, with the 10-year metastasis-free probability being only 24% for the poor group, compared with 85% for the good group. In contrast, this gene expression pattern is much less correlated with the outcome in other patient subpopulations. The methods described here also illustrate the value of combining clinical variables, biological insight, and machine-learning to dissect biological complexity. Our work presented here may contribute a crucial step towards rational design of personalized treatment.
引用
收藏
页码:4059 / 4066
页数:8
相关论文
共 36 条
  • [31] A gene-expression signature as a predictor of survival in breast cancer.
    van de Vijver, MJ
    He, YD
    van 't Veer, LJ
    Dai, H
    Hart, AAM
    Voskuil, DW
    Schreiber, GJ
    Peterse, JL
    Roberts, C
    Marton, MJ
    Parrish, M
    Atsma, D
    Witteveen, A
    Glas, A
    Delahaye, L
    van der Velde, T
    Bartelink, H
    Rodenhuis, S
    Rutgers, ET
    Friend, SH
    Bernards, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) : 1999 - 2009
  • [32] Prognostic value of proliferation in invasive breast cancer: a review
    van Diest, PJ
    van der Wall, E
    Baak, JPA
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) : 675 - 681
  • [33] Gene expression profiling predicts clinical outcome of breast cancer
    van't Veer, LJ
    Dai, HY
    van de Vijver, MJ
    He, YDD
    Hart, AAM
    Mao, M
    Peterse, HL
    van der Kooy, K
    Marton, MJ
    Witteveen, AT
    Schreiber, GJ
    Kerkhoven, RM
    Roberts, C
    Linsley, PS
    Bernards, R
    Friend, SH
    [J]. NATURE, 2002, 415 (6871) : 530 - 536
  • [34] Predicting the clinical status of human breast cancer by using gene expression profiles
    West, M
    Blanchette, C
    Dressman, H
    Huang, E
    Ishida, S
    Spang, R
    Zuzan, H
    Olson, JA
    Marks, JR
    Nevins, JR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) : 11462 - 11467
  • [35] Identification of genes periodically expressed in the human cell cycle and their expression in tumors
    Whitfield, ML
    Sherlock, G
    Saldanha, AJ
    Murray, JI
    Ball, CA
    Alexander, KE
    Matese, JC
    Perou, CM
    Hurt, MM
    Brown, PO
    Botstein, D
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (06) : 1977 - 2000
  • [36] Zajchowski DA, 2001, CANCER RES, V61, P5168